Vertex Pharmaceuticals ( VRTX) reported fourth-quarter revenue and offered an outlook for 2025 that topped analysts’ expectations. The company said it anticipates 2025 revenue of $11.75 billion to $12 ...

Vertex won FDA approval for its newest CF drug, Alyftrek on Dec. 20, 2024. This therapy seems likely to become the new standard of care for CF with its powerful efficacy and convenient once-per ...

Along with its gene editing therapy Casgevy, Vertex is offering fertility preservation support for its patients—a program that the HHS claims violates anti-kickback statutes. In a court filing on ...

Next: Access Our New, Shockingly Simple 'Alert System' RBC Capital Markets says Vertex management is optimistic about the recently approved Alyftrek. They predict that most of the 6,000 patients ...

albeit with some questions about its efficacy relative to Vicodin standard-of-care. Vertex has been running a number of trials because if there’s one thing that we can take away from the failed ...

Now that Extreme E is on a hiatus while it turns into Extreme H, and World Rallycross has switched to a competition between EVs and combustion, Formula E is back to being the primary fully ...

--(BUSINESS WIRE)--Vertex Pharmaceuticals Incorporated (Nasdaq ... 3 pivotal trial of povetacicept 80 mg vs. placebo on top of standard of care in approximately 480 people with IgAN.